SciNeuro in the News
Press Releases
SciNeuro Participated in Alzheimer’s and Parkinson’s Disease Conference 2024, and Presented a Poster on Its Leading ASO Program SNP614
SciNeuro completes dosing in its Phase 1 clinical trial of SNP318, an oral therapeutic for Alzheimer’s disease and other neurodegenerative diseases
SciNeuro Initiates Phase 1 Clinical Trial with SNP318, a Novel Lp-PLA2 Inhibitor Targeting Neurodegenerative and Inflammatory Diseases
Secarna Pharmaceuticals and SciNeuro Pharmaceuticals enter into research and option agreement in the field of CNS diseases
SciNeuro Pharmaceuticals Announces the Appointment of Guojun Bu, Ph.D., as Chief Scientific Officer, and Provides Update on Pipeline of Novel CNS Therapeutics
SciNeuro Pharmaceuticals Announces a License and Option Agreement with GSK to Progress Development of Novel Therapies for CNS Diseases
News Articles
The news articles below were developed independently and any commentary or opinions are those of the publication.
Publications
Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease
Molecular Neurodegeneration | July 11, 2023
Pushing the boundaries of brain organoids to study Alzheimer’s disease
Trends in Molecular Medicine | June 21, 2023
A TREM2 antibody energizes microglia
Nature Neuroscience | February 10, 2023
Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Molecular Neurodegeneration | January 31, 2023
Media Contact
Jessie Yang
jessie.yang@scineuro.com
